Evidence map›Paper›PMID 37215140›Full record

ArticleFrontiers in immunology2023

Heme oxygenase-1 determines the cell fate of ferroptotic death of alveolar macrophages in COPD.

Yi Li, Ying Yang, Tingting Guo, Chengxin Weng, Yongfeng Yang, Zhoufeng Wang, Li Zhang, Weimin Li

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Host mScientific reports · 2026
    Article
  7. Review
  8. Review
  9. TIM-4International journal of biological sciences · 2026
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yi LiDepartment of Respiratory and Critical Care Medicine, Institute of Respiratory Health, Precision Medicine Key Laboratory, West China Hospital, Sichuan University, Chengdu, China.
Ying YangDepartment of Respiratory and Critical Care Medicine, Institute of Respiratory Health, Precision Medicine Key Laboratory, West China Hospital, Sichuan University, Chengdu, China.
Tingting GuoDepartment of Respiratory and Critical Care Medicine, Institute of Respiratory Health, Precision Medicine Key Laboratory, West China Hospital, Sichuan University, Chengdu, China.
Chengxin WengDepartment of Vascular Surgery, West China Hospital, Sichuan University, Chengdu, China.
Yongfeng YangDepartment of Respiratory and Critical Care Medicine, Institute of Respiratory Health, Precision Medicine Key Laboratory, West China Hospital, Sichuan University, Chengdu, China.
Zhoufeng WangDepartment of Respiratory and Critical Care Medicine, Institute of Respiratory Health, Precision Medicine Key Laboratory, West China Hospital, Sichuan University, Chengdu, China.
Li ZhangDepartment of Respiratory and Critical Care Medicine, Institute of Respiratory Health, Precision Medicine Key Laboratory, West China Hospital, Sichuan University, Chengdu, China.
Weimin LiDepartment of Respiratory and Critical Care Medicine, Institute of Respiratory Health, Precision Medicine Key Laboratory, West China Hospital, Sichuan University, Chengdu, China.
Sichuan University · CNWest China Hospital of Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite an increasing understanding of chronic obstructive pulmonary disease (COPD) pathogenesis, the mechanisms of diverse cell populations in the human lung remain unknown. Using single-cell RNA sequencing (scRNA-Seq), we can reveal changes within individual cell populations in COPD that are important for disease pathogenesis and characteristics. Methods: We performed scRNA-Seq on lung tissue obtained from donors with non-COPD and mild-to-moderate COPD to identify disease-related genes within different cell types. We testified the findings using qRT-PCR, immunohistochemistry, immunofluorescence and Western blotting from 25 additional subjects and RAW 264.7 macrophages. Targeting ferroptosis with the ferroptosis inhibitor ferrostatin-1, iron chelator deferoxamine or HO-1 inhibitor zinc protoporphyrin was administered in the experimental cigarette smoke COPD mouse model. Results: We identified two populations of alveolar macrophages (AMs) in the human lung that were dysregulated in COPD patients. We discovered that M2-like AMs modulate susceptibility to ferroptosis by disrupting lipid and iron homeostasis both in vivo and in vitro. The discrepancy in sensitivity to ferroptosis can be determined and regulated by HO-1. In contrast, M1-like AMs showed the ability to attenuate oxidative stress and exert resistance to ferroptosis. In addition, the expression of genes within M2-like AMs is also involved in defects in phagocytosis and lysosome distortion. This ferroptotic phenotype was ameliorated by antiferroptotic compounds, iron chelators and HO-1 inhibitors. During COPD, the accumulation of lipid peroxidation drives ferroptosis-sensitive M2-like AMs, while M1-like AMs show characteristics of ferroptosis resistance. Ferroptotic M2 AMs lose their anti-inflammatory and repair functions but provoke inflammatory responses, resulting in consistent inflammation and tissue damage in the presence of M1 AMs in COPD. Conclusion: Appropriate interventions in ferroptosis can reduce the occurrence of infections and acute onset, and delay the COPD process.

Indexed as

Macrophages, AlveolarPulmonary Disease, Chronic ObstructiveAnimalsHeme Oxygenase-1HumansLungMacrophagesMiceHeme Oxygenase-1alveolar macrophages (AMs)chronic obstructive pulmonary disease (COPD)ferroptosisimmune responseRNA sequencing

Identifiers

PMID37215140
PMCPMC10196003
OpenAlexW4377565434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.